<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347125</url>
  </required_header>
  <id_info>
    <org_study_id>CLD 0201</org_study_id>
    <nct_id>NCT01347125</nct_id>
  </id_info>
  <brief_title>ImCardia for DHF to Treat Diastolic Heart Failure (DHF) Patient a Pilot Study</brief_title>
  <acronym>ImCardia</acronym>
  <official_title>ImCardia for DHF - Safety and Functionality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CorAssist Cadiovascular Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CorAssist Cadiovascular Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the ImCardia safety and to demonstrate system
      functionality in patients undergoing AV replacement with respect to 36 months follow up.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    CorAssist believes that certain improvements are needed to the device
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Adverse event reporting</measure>
    <time_frame>36 month</time_frame>
    <description>Adverse event reporting will continue up to 36 month follow up. Any complication attributed to the device will be recorded.
Any Major Adverse Cardiac Event (MACE) will be evaluated in a safety committee composed from company representative and a cardiosurgeon which is not part of the company</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functionality - Successful Device implantation</measure>
    <time_frame>Immediately post implantation day</time_frame>
    <description>The surgeon will score device implantation procedure post operation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Heart Failure With Normal Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>ImCardia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aortic Stenosis patients candidates for Aortic Valve Replacement (AVR) implanted with the ImCardia device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AVR control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Aortic stenosis patients candidates for aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ImCardia Device</intervention_name>
    <description>The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance</description>
    <arm_group_label>ImCardia</arm_group_label>
    <other_name>IMC 01</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female able to understand and sign a informed consent

          2. Be 50 years of age or older

          3. NYHA class III, IV

          4. EF &gt;55%

          5. Candidates for aortic valve replacement due to aortic stenosis.

          6. Agrees to attend all follow- up evaluations

        Exclusion Criteria:

          1. Free wall thickness less than11.5mm

          2. Adhesions are expected from a previous surgery or medical condition (e.g. s/p chest
             radiation therapy etc.)

          3. Presence of significant myocardial scars (e.g. postinfarction) at proposed site for
             implant of ImCardia™device Attachment screw.

          4. Likely to be need CABG following the implantation of the ImCardia™

          5. Intra-cardiac thrombus/mass

          6. Myocarditis

          7. Acute/chronic pericarditis

          8. Not a candidate for sternotomy

          9. Active infection

         10. Stroke, surgery or ICD within 3 months

         11. Acute coronary syndrome during the past 6 months

         12. Left ventricular regional wall motion abnormalities

         13. Significant valvular disease other that aortic stenosis

         14. Significant pulmonary disease

         15. A history of alcohol abuse, drug addiction, or other psychosocial condition that would
             preclude successful participation, or clear judgment and informed consent in the
             opinion of the Principal Investigator

         16. Participating in another trial (other than non-therapeutic or interventional
             observation) within the last 60 days.

         17. History of noncompliance to medical therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lea Lak, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>CorAssist Cardiovascular</affiliation>
  </overall_official>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>May 3, 2011</last_update_submitted>
  <last_update_submitted_qc>May 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Lea Lak</name_title>
    <organization>CorAssist Cardiovascular Ltd.</organization>
  </responsible_party>
  <keyword>DHF (diastolic heart failure)</keyword>
  <keyword>HFNEF (heart failure with normal ejection fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

